Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency (NCT01016392) | BioMarin Pharmaceutical | 2009-12-01 |
Track Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency automatically
Every clearance here is in the API, with alerts when new ones post.